28 results
424B5
GNLX
Genelux Corp
24 May 24
Prospectus supplement for primary offering
5:19pm
arrangements or other contractual relationships with third parties and otherwise execute our development strategy.
A substantial number of shares … strategy, research and development costs; the anticipated timing, costs and conduct of our clinical trials for our only product candidate, Olvi-Vec
424B5
GNLX
Genelux Corp
23 May 24
Prospectus supplement for primary offering
4:59pm
execute our development strategy.
A substantial number of shares of common stock may be sold in the market following this offering, which may depress … future results of operations and financial position, business strategy, research and development costs; the anticipated timing, costs and conduct of our
S-3
GNLX
Genelux Corp
2 Feb 24
Shelf registration
4:36pm
strategy, research and development costs; the anticipated timing, costs and conduct of our clinical trials for our only product candidate, Olvi-Vec … and financial position, business strategy, research and development costs; the anticipated timing, costs and conduct of our clinical trials for our only
DEF 14A
jdpleoy04
20 Jul 23
Definitive proxy
4:05pm
10-Q
02qlg uakibcbzwrl66
15 May 23
Quarterly report
12:00am
10-K
n04krrqpx7lmtfdgc23
29 Mar 23
Annual report
5:12pm
FWP
jlxzsim
4 Nov 22
Free writing prospectus
3:15pm
S-1/A
w3komn
29 Aug 22
IPO registration (amended)
4:01pm
S-1
EX-10.18
kawb r5bug
24 Jun 22
IPO registration
4:35pm
S-1
fvgrto u0hr
24 Jun 22
IPO registration
4:35pm
S-1
EX-10.11
g7o8kc82vft sxcm
24 Jun 22
IPO registration
4:35pm
DRS/A
EX-10.11
cw2gbq7i
20 May 22
Draft registration statement (amended)
12:00am